Development of HPMA copolymer-anticancer conjugates: clinical experience and lessons learnt

Area of Science:

• Polymer Chemistry
• Medicinal Chemistry
• Oncology

Background:

• Polymer-drug conjugates offer a strategy to improve cancer treatment by leveraging passive tumor targeting and enhanced cellular drug delivery.
• N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers have emerged as a viable polymer platform for developing these conjugates.

Purpose of the Study:

• To review the development and clinical evaluation of HPMA copolymer-drug conjugates as anticancer therapeutics.
• To assess the potential of HPMA copolymer conjugates in improving the therapeutic index of existing chemotherapeutics.

Main Methods:

• Review of preclinical and clinical data for HPMA copolymer conjugates, including FCE28068 (doxorubicin), FCE28069 (doxorubicin with galactose), PNU 166945 (paclitaxel), PNU 166148 (camptothecin), and AP5280/AP5346 (platinates).
• Analysis of rational design principles, including enhanced permeability and retention (EPR) effect and lysosomotropic drug delivery.

Main Results:

• The first synthetic polymer-based anticancer conjugate, FCE28068, demonstrated activity in chemotherapy-refractory patients and confirmed the safety of the HPMA platform.
• Subsequent HPMA copolymer conjugates targeting specific organs (e.g., liver) or utilizing different chemotherapeutics have been investigated in Phase I/II trials.
• Preclinical and clinical observations provide valuable insights into the efficacy and safety of polymer-drug conjugates.

Conclusions:

• HPMA copolymer-drug conjugates have shown promise as a new class of anticancer therapeutics.
• The accumulated data from these conjugates should inform the design and development of next-generation polymer-based cancer treatments.